Safety and efficacy of cyclin-dependent kinase inhibitor rechallenge following ribociclib-induced limiting hypertransaminasemia

Jesús Fuentes-Antrás a,*, Alicia de Luna a, Alfonso López de Sá a, Alberto Ocaña a, b, José Ángel García-Sáenz a, Fernando Moreno a

a Breast Cancer Unit, Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain
b Experimental Therapeutics and Translational Oncology Unit, Department of Medical Oncology, San Carlos University Hospital, Madrid, Spain

1. Introduction

Palbociclib, ribociclib, and abemaciclib, are well-tolerated, orally active, cyclin-dependent kinase inhibitors (CDKIs), each approved for hormone-positive (HR+) HER2-negative metastatic breast cancer (MBC) following pivotal trials showing substantial progression-free survival (PFS) benefit in the first and second-line settings in combination with ET, while abemaciclib is also approved as monotherapy for pre-treated patients [1–6]. Although these drugs share a similar molecular mechanism of action and metabolism by the CYP3A4, they differ substantially in terms of half-life, IC50, and their binding avidity to different CDK molecules, which could contribute to the disparity in their toxicity profiles [7]. As reported by large randomized clinical trials (RCTs), neutropenia was the most common side effect of palbociclib and ribociclib, while diarrhea was the most frequent with abemaciclib. Hypertransaminasemia has emerged as a concern with ribociclib and abemaciclib, resulting in regulatory warnings and recommendations for monitoring liver function tests. It remains unclear whether liver injury might be due to toxic metabolites, immunogenic intermediates, and/or on-target effects on hepatocytes. In this regard, grade $\geq$3 elevation of alanine and aspartate aminotransferases occurred in up to 11% and 6% of patients receiving ribociclib or abemaciclib in RCTs [2,4,8]. To date, the scarcity of data on cross toxicity and cross efficacy between CDKIs narrows the use of rechallenge strategies in patients who discontinued ribociclib due to liver toxicity.

2. Materials and methods

We retrospectively reviewed the case records of patients with HR+ /HER2- MBC treated with ribociclib at the San Carlos University Hospital, Madrid, Spain, both in clinical trials and clinical practice, from January 2017 to May 2020. Patients in whom ribociclib was discontinued due to grade $\geq$3 hypertransaminasemia, and who subsequently received palbociclib or abemaciclib, were included in the analysis. The Common Terminology Criteria for Adverse Events (CTCAE, v5.0) was utilized. Drugs were prescribed at full doses unless otherwise indicated. This study was approved by the Ethics Committee of the San Carlos University Hospital and performed in accordance with the Declaration of Helsinki. Informed consent was waived due to its retrospective nature.

* Corresponding author.
E-mail address: jfuentesa@salud.madrid.org (J. Fuentes-Antrás).

https://doi.org/10.1016/j.breast.2020.10.007
0960-9776/© 2020 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
3. Results

Sixty-four HR+/HER2- MBC patients were exposed to ribociclib in our institution during the investigation period. Hypertransaminasemia of any grade occurred in 14 patients (21.9%), of which grade ≥3 occurred in 7 patients (10.9%). Ribociclib was interrupted and reintroduced with dose reductions in 3 patients, while it was definitely discontinued in 7 patients. Six of them were subsequently treated with a different CDKI and composed the final cohort of the study. Median age was 49.5 years (range 45–61) and all patients were female and ECOG 0. Only 1 patient had liver metastasis and only 1 patient had bone metastasis exclusively. In 5 patients, letrozole plus ribociclib was prescribed as first line therapy for metastatic disease, and in 1 patient, fulvestrant plus ribociclib was initiated as fourth line therapy (Fig. 1). None of the patients had a history of previous liver disease, and neither received hepatotoxic concomitant medications. All patients stopped treatment because of toxicity, but none of them presented symptoms other than mild asthenia and gastrointestinal complaints.

The median number of cycles of ribociclib before treatment withdrawal was 4.5 (1.5–5) (Fig. 1). Liver toxicity reached grade 3 in 4 of the patients, and grade 4 in 2 of them. The median follow-up after treatment discontinuation was 19.5 months (7–36). Viral serology for hepatotropic viruses was negative, and an autoimmune liver disease panel including antinuclear antibodies and antibodies against parietal cells, LC1, LKM, M2, smooth muscle, and reticulin, was performed in 5 of the 6 patients displaying no abnormalities. No patient was biopsied. Patients #1, 2, 3, and 5 reached peaking values of transaminases early after treatment interruption (0–1 week), while it took 10 weeks for patients #4 and 6. Remarkably, patient #3 met criteria for the biochemical Hy’s law (elevated bilirubin levels without cholestasis). The median time to recovery was 13.5 weeks (6–26). By maintaining the endocrine therapy partner as monotherapy beyond ribociclib withdrawal, 4 patients attained a partial response by RECIST and the median PFS was 10.5 months (7–13).

The drugs of choice for the rechallenge strategy were palbociclib plus fulvestrant in 4 patients, palbociclib plus letrozole in 1 patient, and abemaciclib plus letrozole in 1 patient. These regimens were initiated after progression to the remaining endocrine partner in 4 of the patients, right after normalization of transaminases in 1 patient, and 1.5 years later in 1 patient. No elevation of transaminases has been observed after a median follow-up of 6 months (2–27). In terms of efficacy, patient #1 remains on treatment with almost complete response after 27 months, while patients #3 and 4 progressed at 6 months of therapy, and patient #5 progressed at 10 months patients. Patients #2 and 6 have not been yet evaluated radiologically after 6 and 2 months of therapy, respectively.

4. Discussion

To the best of our knowledge, here we present the largest case series to date showing the safety and efficacy of utilizing palbociclib or abemaciclib in HR+/HER2- MBC patients who had experienced unacceptable ribociclib-induced hypertransaminasemia. The incidence of grade ≥3 hypertransaminasemia in our series was consistent with that reported by RCTs (10.9% vs 5–11%). In the MONALEESA trials, grade ≥3 hypertransaminasemia led to the discontinuation of ribociclib/placebo. In grade 3 toxicity, however, the drug could be resumed at a lower dose level if grade ≤1 was restored in ≤21 days and in the absence of recurrences [2,5,8]. Only two individual case reports have been published addressing this issue, both of them describing young post-menopausal women with HR+/HER-bone-only MBC who received ribociclib plus letrozole as first line regimen and switched to palbociclib after grade ≥3 liver toxicity [9,10]. In both cases, administration of palbociclib did not elicit liver toxicity of any grade, and patients achieved durable responses after 1 year of follow-up. However, there is no evidence on the sequential use of CDKIs in women with MBC including visceral involvement or >1 previous lines of therapy. Also, it is unclear whether the continuation of the endocrine partner alone can negatively impact the efficacy of other CDKIs compared to immediate switching after liver function recovery.

Ongoing studies will shed light on this controversy, although specific prospective and randomized initiatives are required. We expect results from the phase II PACE (NCT03147287) and PALMIRA (NCT02732119) trials evaluating the activity of combinations including palbociclib in HR+/HER- MBC patients that have previously stopped responding to prior palbociclib. Similarly, the phase II portion of the TRINITI trial (NCT02732119) will report on the antitumor activity of ribociclib following progression on a CDKI.

We hope that these data can assist clinicians and their patients in making individualized decisions in such an ominous scenario as metastatic disease, in which the limited resources must be managed in a timely manner to obtain the maximum efficacy and prolong patient well-being as much as possible.

Ethics approval and consent to participate

This study was approved by the Ethics Committee of the San Carlos University Hospital and performed in accordance with the Declaration of Helsinki. Informed consent was waived due to its retrospective and descriptive nature.

Funding

No funding resources.

Acknowledgements

We want to thank our clinical colleagues from the Medical Oncology Department for the critical reading of the manuscript and improving suggestions.

References

[1] Finn RS, Martin M, Rugo HS, Jones S, Im S-A, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925–36. https://doi.org/10.1056/NEJMoa1607305.
[2] Hortobagyi GN, Stemmer SM, Burris HA, Yap Y-S, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 2016;375:1738–48. https://doi.org/10.1056/NEJMoa1609705.
[3] Turner NC, Slamon DJ, Ro J, Bondarenko I, Im S-A, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med 2018;379:1926–36. https://doi.org/10.1056/NEJMoa1810527.
[4] Johnston S, Martin M, Di Leo A, Im S-A, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. Npj Breast Canc 2019;5:1–8. https://doi.org/10.1038/s41523-018-0097-2.
[5] Slamon DJ, Neven P, Chia S, Fasching PA, Laurentiis MD, Im S-A, et al. Overall...
survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2019. https://doi.org/10.1056/NEJMoa1911149.

[6] Sledge GW, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor–positive, ERBB2-negative breast cancer that progressed on endocrine therapy—MONARCH 2: a randomized clinical trial. JAMA Oncol 2020;6:116–24. https://doi.org/10.1001/jamaoncol.2019.4782.

[7] Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 inhibitors in breast cancer: current controversies and future directions. Curr Oncol Rep 2019;21:25. https://doi.org/10.1007/s11912-019-0769-3.

[8] Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med 2019;381:107–16. https://doi.org/10.1056/NEJMoa1903765.

[9] Farhat F, Tarabaih M, Kanj A, Aoun M, Kattan J, Assi T, et al. Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient. Anti Canc Drugs 2020;31:85–9. https://doi.org/10.1097/CAD.0000000000000945.

[10] Meynard L, Grellety T. CDK 4/6 inhibitor successful rechallenge after limiting hepatic toxicity. Breast J 2020;26:255–7. https://doi.org/10.1111/tbj.13532.